Show simple item record

dc.contributor.authorKüblbeck, Jenni
dc.contributor.authorVuorio, Taina
dc.contributor.authorNiskanen, Jonna
dc.contributor.authorFortino, Vittorio
dc.contributor.authorBraeunin, Albert
dc.contributor.authorAbass, Khaled
dc.contributor.authorRautio, Arja
dc.contributor.authorHakkola, Jukka
dc.contributor.authorHonkakoski, Paavo
dc.contributor.authorLevonen, Anna-Liisa
dc.date.accessioned2020-05-08T07:53:05Z
dc.date.available2020-05-08T07:53:05Z
dc.date.issued2020
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/8116
dc.description.abstractEndocrine disruptors (EDs) are defined as chemicals that mimic, block, or interfere with hormones in the body’s endocrine systems and have been associated with a diverse array of health issues. The concept of endocrine disruption has recently been extended to metabolic alterations that may result in diseases, such as obesity, diabetes, and fatty liver disease, and constitute an increasing health concern worldwide. However, while epidemiological and experimental data on the close association of EDs and adverse metabolic e ects are mounting, predictive methods and models to evaluate the detailed mechanisms and pathways behind these observed e ects are lacking, thus restricting the regulatory risk assessment of EDs. The EDCMET (Metabolic e ects of Endocrine Disrupting Chemicals: novel testing METhods and adverse outcome pathways) project brings together systems toxicologists; experimental biologists with a thorough understanding of the molecular mechanisms of metabolic disease and comprehensive in vitro and in vivo methodological skills; and, ultimately, epidemiologists linking environmental exposure to adverse metabolic outcomes. During its 5-year journey, EDCMET aims to identify novel ED mechanisms of action, to generate (pre)validated test methods to assess the metabolic e ects of Eds, and to predict emergent adverse biological phenotypes by following the adverse outcome pathway (AOP) paradigm.
dc.language.isoenglanti
dc.publisherMDPI AG
dc.relation.ispartofseriesInternational journal of molecular sciences
dc.relation.urihttp://dx.doi.org/10.3390/ijms21083021
dc.rightsCC BY http://creativecommons.org/licenses/by/4.0/
dc.subjectendocrine disruptors (EDs)
dc.subjectnuclear receptors (NRs)
dc.subjectmetabolism
dc.subjectmetabolic syndrome
dc.subjectobesity
dc.subjectrisk assessment
dc.subjecthuman health
dc.subjectadverse outcome pathway (AOP)
dc.subjectassay validation
dc.titleThe EDCMET project: Metabolic effects of endocrine disruptors
dc.description.versionpublished version
dc.contributor.departmentA.I. Virtanen -instituutti
dc.contributor.departmentSchool of Medicine / Biomedicine,School of Pharmacy, Activities
uef.solecris.id70219529en
dc.type.publicationTieteelliset aikakauslehtiartikkelit
dc.rights.accessrights© the authors
dc.relation.projectidinfo:eu-repo/grantAgreement/EC/H2020-EU.3.1.1./825762/EU/Metabolic effects of Endocrine Disrupting Chemicals: novel testing METhods and adverse outcome pathways/EDCMET
dc.relation.doi10.3390/ijms21083021
dc.description.reviewstatuspeerReviewed
dc.format.pagerange3021
dc.publisher.countrySveitsi
dc.relation.issn1661-6596
dc.relation.issue8
dc.relation.volume21
dc.rights.accesslevelopenAccess
dc.type.okmB1
uef.solecris.openaccessOpen access -julkaisukanavassa ilmestynyt julkaisu


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record